

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-Nov-2020
 Document Type: USP Monographs
 DocId: GUID-6FCEAE6-B5EA-4209-9026-F904E4083C5D_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M20546_02_01
 DOI Ref: 234kl

© 2025 USPC
 Do not distribute

Cromolyn Sodium Ophthalmic Solution

DEFINITION

Cromolyn Sodium Ophthalmic Solution is a sterile, aqueous solution of Cromolyn Sodium. It contains NLT 90.0% and NMT 110.0% of the labeled amount of cromolyn sodium ($C_{23}H_{14}Na_2O_{11}$). It may contain suitable antimicrobial and stabilizing agents.

IDENTIFICATION

• **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

Add the following:

▲ **B.** The UV absorption spectrum of the major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution*, as obtained in the Assay. ▲ (USP 1-Aug-2020)

ASSAY

Change to read:

PROCEDURE

Buffer: 5.6 g/L of [monobasic potassium phosphate](#) and 22.2 g/L of [myristyltrimethylammonium bromide](#) in [water](#). Adjust with ▲ [50% sodium hydroxide TS](#) ▲ (USP 1-Aug-2020) to a pH of 6.5.

Mobile phase: Methanol and *Buffer* (55:45)

Diluent: Acetonitrile and water (30:70)

System suitability solution: 0.5 mg/mL of [USP Cromolyn Sodium RS](#) and 0.02 mg/mL each of [USP Cromolyn Related Compound A RS](#) and [USP Cromolyn Related Compound B RS](#) in *Diluent*

Standard solution: 0.5 mg/mL of [USP Cromolyn Sodium RS](#) in *Diluent*. Sonication may be needed to aid dissolution.

Sample solution: Nominally equivalent to 0.5 mg/mL of cromolyn sodium from a volume of Ophthalmic Solution in *Diluent*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 326 nm. ▲ For *Identification B*, use a diode array detector in the range of 220–400 nm. ▲ (USP 1-Aug-2020)

Column: 4.6-mm × 10-cm; 3.5-μm packing [L7](#)

Column temperature: 40°

Flow rate: 1.5 mL/min

Injection volume: 20 μL

▲ **Run time:** NLT 2 times the retention time of cromolyn ▲ (USP 1-Aug-2020)

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—See [Table 1](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 2.0 between cromolyn related compound B and cromolyn related compound A; NLT 2.0 between cromolyn related compound A and cromolyn, ▲ (USP 1-Aug-2020) *System suitability solution*

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 0.73%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of cromolyn sodium ($C_{23}H_{14}Na_2O_{11}$) in the portion of Ophthalmic Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of cromolyn from the *Sample solution*

r_S = peak response of cromolyn from the *Standard solution*

C_S = concentration of [USP Cromolyn Sodium RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

IMPURITIES

Change to read:

• ORGANIC IMPURITIES

Mobile phase, Diluent, and System suitability solution: Prepare as directed in the Assay.

Standard solution: 0.002 mg/mL each of [USP Cromolyn Related Compound A RS](#), [USP Cromolyn Related Compound B RS](#), and [USP Cromolyn Sodium RS](#) in *Diluent*

Sample solution: Nominally equivalent to 2 mg/mL of cromolyn sodium from a volume of Ophthalmic Solution in *Diluent*

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 326 nm

Column: 4.6-mm × 10-cm; 3.5-μm packing [L7](#)

Temperatures

Autosampler: 4°

Column: 40°

Flow rate: 1.5 mL/min

Injection volume: 20 μL

Run time: ▲NLT▲ (USP 1-Aug-2020) 2 times the retention time of cromolyn

System suitability

Samples: *System suitability solution* and *Standard solution*

▲[NOTE—See [Table 1](#) for the relative retention times.]▲ (USP 1-Aug-2020)

Suitability requirements

Resolution: NLT 2.0 between cromolyn related compound B and cromolyn related compound A; NLT 2.0 between cromolyn related compound A and cromolyn, ▲▲ (USP 1-Aug-2020) *System suitability solution*

Relative standard deviation: NMT 3% for 6 replicate injections, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of ▲▲ (USP 1-Aug-2020) cromolyn related compound ▲A or cromolyn related compound B▲ (USP 1-Aug-2020) in the portion of Ophthalmic Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of cromolyn related compound A or cromolyn related compound B from the *Sample solution*

r_S = peak response of cromolyn related compound A or cromolyn related compound B from the *Standard solution*

C_S = concentration of ▲[USP Cromolyn Related Compound A RS](#) or [USP Cromolyn Related Compound B RS](#)▲ (USP 1-Aug-2020) in the *Standard solution* (mg/mL)

C_U = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Calculate the percentage of any individual unspecified degradation product in the portion of Ophthalmic Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each ▲individual▲ (USP 1-Aug-2020) unspecified degradation product from the *Sample solution*

r_S = peak response of cromolyn from the *Standard solution*

C_s = concentration of [USP Cromolyn Sodium RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 1](#).

Table 1

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Cromolyn related compound B	0.4	0.75
Cromolyn related compound A	0.5	0.75
Cromolyn sodium	1.0	—
Any individual unspecified degradation product	—	0.75
Total impurities	—	2.0

SPECIFIC TESTS

- [pH \(791\)](#): 4.0–7.0
- [STERILITY TESTS \(71\)](#): Meets the requirements

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant, single-dose or multiple-dose containers. Ophthalmic Solution that is packaged in multiple-dose containers contains a suitable antimicrobial agent. Store between 15° and 30°.
- [USP REFERENCE STANDARDS \(11\)](#).
 - [USP Cromolyn Related Compound A RS](#)
1,3-Bis(2-acetyl-3-hydroxyphenoxy) propan-2-ol.
 $C_{19}H_{20}O_7$ 360.36
 - [USP Cromolyn Related Compound B RS](#)
Diethyl 5,5'-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylate).
 $C_{27}H_{24}O_{11}$ 524.48
 - [USP Cromolyn Sodium RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CROMOLYN SODIUM OPHTHALMIC SOLUTION	Documentary Standards Support	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 45(3)

Current DocID: GUID-6FCEAEA6-B5EA-4209-9026-F904E4083C5D_2_en-US

DOI: https://doi.org/10.31003/USPNF_M20546_02_01

DOI ref: [234kl](#)